Explore Cardarine dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Cardarine (GW-501516) is a small-molecule PPARδ agonist whose development was halted after rodent studies showed cancer formation; it is banned in sport by WADA. It is not a peptide or SARM, so the certificate of analysis (COA) is about chemical purity and accurate dosing.
Cardarine binds and activates PPARδ, a nuclear receptor highly expressed in skeletal muscle, liver, and adipose tissue. Activation drives a transcriptional program favouring fatty-acid oxidation, mitochondrial biogenesis, and shift toward slow-twitch oxidative muscle fibre type — the pharmacology behind the "endurance" framing the consumer market sells it on.[4] At sufficient duration of exposure in rodent carcinogenicity studies, PPARδ agonism also drives chronic cellular-proliferation signalling that translated into the multi-organ tumour formation that ended clinical development.[1][2]
A short Phase 2 in dyslipidemia showed measurable improvement in HDL cholesterol and triglycerides over 12 weeks.[5] The development program ended after the 2-year rodent carcinogenicity studies; subsequent GlaxoSmithKline / regulatory reporting and a WADA scientific committee review confirmed the carcinogenicity signal across multiple tissues at multiple doses.[1][2][3] Cardarine is occasionally cited in pre-clinical metabolic and exercise-mimetic research, but no Phase 2 or Phase 3 trial has been conducted in any indication after development was halted. WADA also reported a measurable population of athlete adverse-analytical findings for GW-501516 following the explicit prohibition.[3]
Not FDA-approved; development was terminated by GlaxoSmithKline in 2007 after rodent multi-organ carcinogenicity. WADA-prohibited at all times under S4.5 with an explicit safety warning. Research-grade material only.
Cardarine has a reported half-life of ~16–24 hours (estimated). The pharmacokinetic reference models an interval of once daily (oral); this is not a measured community cadence or a dosing recommendation. Roughly a day-long half-life means once-daily dosing keeps a fairly steady level, with some buildup over the first few days. Pharmacokinetic source: No published human PK; pre-clinical PPARδ agonist (GlaxoSmithKline GW501516). It is catalogued under Other Peptides on WPA.
1 Cardarine reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.